Literature DB >> 2369679

The clinical spectrum of infections with viridans streptococci in bone marrow transplant patients.

J G Villablanca1, M Steiner, J Kersey, N K Ramsay, P Ferrieri, R Haake, D Weisdorf.   

Abstract

A retrospective review of 832 bone marrow transplant patients was performed to determine the clinical spectrum and risk factors for viridans streptococci infections. The incidence of viridans streptococci cultured from the blood and/or cerebrospinal fluid was 15% (123/832), occurring within 15 days of bone marrow transplant in 78% of patients, usually during profound neutropenia. Strep. mitis was the most frequent isolate (47%). Only 27% (33/123) of patients were symptomatic beyond fever, usually with neurologic, pulmonary, and/or cardiovascular manifestations. Ten (8%) of 123 culture positive patients developed a fulminant cardiorespiratory collapse, with a 60% mortality. One additional death occurred due to cerebritis. However, a time dependent covariate analysis found no significant difference in overall mortality (p = 0.30) or duration of hospitalization (p = 0.50) in patients with or without viridans streptococci infections. A multivariate analysis revealed that age less than 18 years (RR = 1.5, p = 0.04) and a primary diagnosis of acute lymphocytic leukemia (RR = 1.5, p = 0.07) were independent and significant risk factors for viridans streptococci infections. Sex, conditioning regimen, donor type, in vitro bone marrow treatment, and acute graft-versus-host disease were not significant. Viridans streptococci should be recognized as pathogens in bone marrow transplant patients which require appropriate antibiotics and aggressive supportive therapy.

Entities:  

Mesh:

Year:  1990        PMID: 2369679

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  11 in total

1.  Granulocyte colony-stimulating factor (G-CSF) treatment in a neutropenic leukemia patient with diffuse interstitial pulmonary infiltrates.

Authors:  A Heyll; C Aul; F Gogolin; M Thomas; M Arning; A Gehrt; U Hadding
Journal:  Ann Hematol       Date:  1991-12       Impact factor: 3.673

2.  Lack of ability of ciprofloxacin-rifampin prophylaxis to decrease infection-related morbidity in neutropenic patients given cytotoxic therapy and peripheral blood stem cell transplants.

Authors:  M Hidalgo; J Hornedo; C Lumbreras; J M Trigo; C Gómez; S Perea; A Ruiz; R Hitt; H Cortés-Funes
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

3.  Randomized trial of the addition of gram-positive prophylaxis to standard antimicrobial prophylaxis for patients undergoing autologous bone marrow transplantation.

Authors:  E R Broun; J L Wheat; P H Kneebone; K Sundblad; R A Hromas; G Tricot
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

4.  Prevention of viridans-group streptococcal septicemia in oncohematologic patients: a controlled comparative study on the effect of penicillin G and cotrimoxazole.

Authors:  H F Guiot; J W van der Meer; P J van den Broek; R Willemze; R van Furth
Journal:  Ann Hematol       Date:  1992-06       Impact factor: 3.673

5.  Genetic loci of Streptococcus mitis that mediate binding to human platelets.

Authors:  B A Bensing; C E Rubens; P M Sullam
Journal:  Infect Immun       Date:  2001-03       Impact factor: 3.441

6.  Streptococcus sanguis-induced platelet clotting in rabbits and hemodynamic and cardiopulmonary consequences.

Authors:  M W Meyer; K Gong; M C Herzberg
Journal:  Infect Immun       Date:  1998-12       Impact factor: 3.441

7.  A randomized trial of roxithromycin in patients with acute leukemia and bone marrow transplant recipients receiving fluoroquinolone prophylaxis.

Authors:  W V Kern; B Hay; P Kern; R Marre; R Arnold
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

Review 8.  Bacteremia caused by Stomatococcus mucilaginosus: report of seven cases and review of the literature.

Authors:  A Kaufhold; R R Reinert; W Kern
Journal:  Infection       Date:  1992 Jul-Aug       Impact factor: 3.553

9.  Prevalence of penicillin-resistant viridans streptococci in healthy children and in patients with malignant haematological disorders.

Authors:  H F Guiot; L J Corel; J M Vossen
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-08       Impact factor: 3.267

10.  Defining antibody targets in Streptococcus oralis infection.

Authors:  J P Burnie; W Brooks; M Donohoe; S Hodgetts; A al-Ghamdi; R C Matthews
Journal:  Infect Immun       Date:  1996-05       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.